Xin Liang, Xin Deng, Qiying Lao, Longqian Chen, Yanli Liang, Liu Yang
{"title":"Feasibility and efficacy of remimazolam for anesthesia monitoring in transcatheter aortic valve implantation via femoral artery access.","authors":"Xin Liang, Xin Deng, Qiying Lao, Longqian Chen, Yanli Liang, Liu Yang","doi":"10.62347/QUMD4078","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of remimazolam during anesthesia monitoring in transcatheter aortic valve implantation (TAVI) via femoral artery catheter (FAC).</p><p><strong>Methods: </strong>We reviewed the medical records of 50 patients who underwent TAVI via FAC from July 2022 to September 2023. Patients were divided into two groups: a control group (receiving propofol, n=25) and a remimazolam group (receiving remimazolam, n=25). Pulse oxygen saturation (SpO<sub>2</sub>), heart rate (HR), mean arterial pressure (MAP) and Bispectral Index (BIS) were recorded at various time points: 5 min before anesthesia (T0), 0 (T1), 5 (T2), 10 (T3), 15 (T4), and 20 min (T5) after infusion. Operation time, blood loss, awakening time, quality of recovery (QoR-15) scores before operation and 1 and 3 days after operation were recorded and compared between the two groups. Additionally, the incidence of delirium at 1-day post-operation was compared between the two groups. The incidence of adverse reactions and patient satisfaction were compared between the groups.</p><p><strong>Results: </strong>At T2, T3, T4 and T5, the remimazolam group exhibited significantly higher SpO<sub>2</sub>, HR and MAP than the control group (P<0.05); BIS values and modified observer's assessment of alertness/sedation (MOAA/S) scores showed no significant differences (P>0.05). The remimazolam group also had significantly earlier awakening times (P<0.05), without differences in operation time or blood loss (P<0.05). QoR-15 scores at 1 and 3 days post-operation were higher in the remimazolam group (P<0.05). The incidence of postoperative delirium was slightly lower in the remimazolam group (P>0.05). The control group had a higher total incidence of adverse reactions and lower satisfaction compared to the remimazolam group (P<0.05).</p><p><strong>Conclusion: </strong>Remimazolam is an effective sedative for TAVI anesthesia, associated with lower postoperative adverse reactions, thus facilitating better recovery.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 5","pages":"3530-3537"},"PeriodicalIF":1.7000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170432/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/QUMD4078","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the effect of remimazolam during anesthesia monitoring in transcatheter aortic valve implantation (TAVI) via femoral artery catheter (FAC).
Methods: We reviewed the medical records of 50 patients who underwent TAVI via FAC from July 2022 to September 2023. Patients were divided into two groups: a control group (receiving propofol, n=25) and a remimazolam group (receiving remimazolam, n=25). Pulse oxygen saturation (SpO2), heart rate (HR), mean arterial pressure (MAP) and Bispectral Index (BIS) were recorded at various time points: 5 min before anesthesia (T0), 0 (T1), 5 (T2), 10 (T3), 15 (T4), and 20 min (T5) after infusion. Operation time, blood loss, awakening time, quality of recovery (QoR-15) scores before operation and 1 and 3 days after operation were recorded and compared between the two groups. Additionally, the incidence of delirium at 1-day post-operation was compared between the two groups. The incidence of adverse reactions and patient satisfaction were compared between the groups.
Results: At T2, T3, T4 and T5, the remimazolam group exhibited significantly higher SpO2, HR and MAP than the control group (P<0.05); BIS values and modified observer's assessment of alertness/sedation (MOAA/S) scores showed no significant differences (P>0.05). The remimazolam group also had significantly earlier awakening times (P<0.05), without differences in operation time or blood loss (P<0.05). QoR-15 scores at 1 and 3 days post-operation were higher in the remimazolam group (P<0.05). The incidence of postoperative delirium was slightly lower in the remimazolam group (P>0.05). The control group had a higher total incidence of adverse reactions and lower satisfaction compared to the remimazolam group (P<0.05).
Conclusion: Remimazolam is an effective sedative for TAVI anesthesia, associated with lower postoperative adverse reactions, thus facilitating better recovery.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
